CVS Health stock has delivered a strong 48.3% return over the past year, yet broader valuation checks still point to shares looking inexpensive relative to the company’s fundamentals.

• Over the past 12 months, CVS Health is up 48.3%, which puts recent weakness into context when considering whether the move has already reflected better fundamentals.
• Investor expectations around higher margin health insurance and pharmacy services can support the current share price, while legal disputes and labor tensions may affect how much value the market is willing to ascribe to future cash flows.
• On Simply Wall St’s broader checks, CVS Health scores high on value, with a 5 out of 6 valuation score, which suggests the stock still screens as relatively inexpensive on several measures.

The stock’s next move may depend on whether that high value score and recent share price strength can both be justified by what investors are paying for CVS Health today.

Is CVS Health Still Cheap on Earnings?

The P/E ratio is a useful way to think about what you are paying for each dollar of CVS Health earnings today. For a mature, diversified healthcare group, it gives a straightforward anchor for comparing against peers and the broader Healthcare industry.

CVS Health currently trades on a P/E of about 24.8x. That is close to the Healthcare industry average of roughly 24.8x and above the peer group average of around 19.1x. However, Simply Wall St’s fair P/E for CVS Health, which weighs its size, risk profile and earnings characteristics, sits at about 36.6x. This indicates that the stock trades at a sizable discount to the level that this framework considers reasonable based on those inputs.

Despite stronger recent earnings announcements and raised guidance in 2026, the P/E multiple still prices CVS Health below this tailored fair ratio benchmark. That gap indicates that the market is not fully reflecting the earnings power that the model is attributing to the company.

On the P/E multiple, CVS Health stock currently screens as undervalued relative to the fair ratio implied by its earnings profile.

The CVS Health Narrative: What Would Justify Today's Price?

Simply Wall St Narratives try to answer the question that follows naturally from CVS Health’s valuation puzzle by spelling out what kind of future for growth, margins and earnings would need to play out for the stock to be worth meaningfully more or less than today’s price. They are available on the company’s Community page. Each narrative links its number to a clear view on where CVS Health’s growth, profitability and key risks might go next, so you can revisit those views as fresh information arrives.

One of the top community narratives on CVS Health: 9% undervalued

"CVS is no longer trying to be a faster pharmacy; it’s trying to be a more complete healthcare system, and that distinction matters more than quarterly volatility suggests…"

Do you think there's more to the story for CVS Health? Head over to our Community to see what others are saying!

The Bottom Line

For investors looking at CVS Health today, the key point is that the stock still appears undervalued on earnings multiples despite the higher P/E versus some peers. The broader valuation checks suggest a market that is cautious about legal and labor risks and may be slow to fully recognize the company’s earnings profile. From here, the real swing factor is whether CVS Health can continue converting its integrated healthcare model into steady, defensible earnings so that the current discount reflects mispricing rather than a value trap.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.